Pharmaceutical News

RSS

Study identifies a new way to make opioids safer

Researchers at the University of Arizona Health Sciences identified a new way to make opioids safer, increasing the pain-relieving properties of opioids while decreasing unwanted side effects through the spinal inhibition of a Heat shock protein 90 isoform.

17 Jul 2024

Marine fungus-derived aniquinazolin B could be a potential opioid alternative

Opioids have long been known as natural substances with substantial pharmacological effect. They have been used as effective painkillers.

17 Jul 2024

Study shows oral semaglutide matches DPP-4i in adherence and persistence for type 2 diabetes

Researchers found that adherence and persistence in T2D patients using oral semaglutide is similar to DPP-4i, but semaglutide users required fewer concurrent medications, indicating higher long-term efficacy.

16 Jul 2024

Harnessing brain proteins for enhanced diabetes and weight-loss drugs

A network of proteins found in the central nervous system could be harnessed to increase the effectiveness and reduce the side effects of popular diabetes and weight-loss drugs, according to new research from the University of Michigan.

15 Jul 2024

Mechanism behind propofol-induced unconsciousness revealed

There are many drugs that anesthesiologists can use to induce unconsciousness in patients. Exactly how these drugs cause the brain to lose consciousness has been a longstanding question, but MIT neuroscientists have now answered that question for one commonly used anesthesia drug.

15 Jul 2024

New research aims to help lessen the risk of opioid misuse and overdose

New research aims to help reduce the quantity of unused prescription opioids after emergency department visits and lessen the risk of opioid misuse and overdose.

15 Jul 2024

Twincretin drug Tirzepatide shows unmatched efficacy in weight loss and diabetes management

Tirzepatide, a novel twincretin drug, significantly improves weight loss and glycemic control in obese and type 2 diabetes patients, outperforming traditional treatments in clinical trials.

15 Jul 2024

AI analysis of Reddit reveals public interest in GLP-1 drugs for weight loss and mental health benefits

Researchers analyzed over 391,000 Reddit discussions using AI to study public perceptions of GLP-1 RAs, finding high interest in weight loss, side effects, and access issues, with mostly neutral-to-positive sentiment.

14 Jul 2024

New brain targets for GLP1-based obesity drugs may reduce weight without nausea

Researchers identified distinct hindbrain GLP1R neurons driving satiety and aversion, offering new targets for effective, side-effect-free obesity treatments.

14 Jul 2024

Groundbreaking mRNA vaccine administered to captive elephant to fight EEHV

Colossal, the de-extinction company, announces that the mRNA vaccine it helped to provide research support and acceleration funding for has been administered to the first elephant in captivity.

13 Jul 2024

Almirall's Ebglyss recommended by NICE for NHS atopic dermatitis patients

Almirall S.A., a global biopharmaceutical company dedicated to medical dermatology, announced today that the National Institute for Health and Care Excellence (NICE) has recommended Ebglyss (lebrikizumab) for use in moderate to severe Atopic Dermatitis in the NHS England.

13 Jul 2024

Study reveals potential cognitive benefits of antidiabetic drugs

Investigators analyzing the potential cognitive effects of antidiabetic medications in records of more than 1.5 million patients with type 2 diabetes mellitus (T2DM) found risks of dementia and Alzheimer's disease (AD) were significantly lower in patients treated with metformin and sodium glucose co-transporter-2 inhibitors (SGLT-2i) compared to other antidiabetic drugs.

12 Jul 2024